ARS Pharmaceuticals (SPRY) Capital Expenditures (2020 - 2025)

ARS Pharmaceuticals has disclosed Capital Expenditures across 6 years of filings, most recently posting -$5.5 million for Q3 2025.

• Capital Expenditures for Q3 2025 came in at -$5.5 million, down 6445.98% year-over-year; the trailing twelve-month figure through Mar 2026 was $248000.0 (down 56.57% YoY), and the FY2025 annual result was $339000.0, down 39.79% from the prior year.
• Capital Expenditures came in at -$5.5 million for Q3 2025 at ARS Pharmaceuticals, down from $5.8 million in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $5.8 million in Q2 2025 to a low of -$5.5 million in Q3 2025.
• The 5-year median for Capital Expenditures is $73000.0 (2022), against an average of $64368.4.
• Across the five-year window, Capital Expenditures soared 13900.0% in 2021 and tumbled 6445.98% in 2025, its largest moves.
• ARS Pharmaceuticals' Capital Expenditures stood at -$767000.0 in 2021, then surged by 102.35% to $18000.0 in 2022, then surged by 366.67% to $84000.0 in 2023, then soared by 466.67% to $476000.0 in 2024, then slumped by 1259.87% to -$5.5 million in 2025.
• The last three Capital Expenditures figures came in at -$5.5 million (Q3 2025), $5.8 million (Q2 2025), and $91000.0 (Q1 2025), per Business Quant data.